Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Pillar expands commercial partnership with Illumina

January 2025—Pillar Biosciences announced an expansion of its existing partnership with Illumina in which a broader portfolio of its OncoReveal NGS panels will be offered directly through Illumina. The additional research use only NGS panels include OncoReveal Core LBx, Essential LBx, and Fusion LBx for liquid biopsy tumor profiling and OncoReveal Multicancer RNA Fusion (18-driver gene RNA panel) and Solid Tumor v2 (48-gene DNA panel) for solid tumor profiling, for use on Illumina’s MiSeq and NextSeq 550 systems.

StatLab launches KT brand slides, cover glass

January 2025—StatLab Medical Products has launched a self-manufactured premium slide and cover glass brand. StatLab KT slides are developed, manufactured, and sold within the StatLab group and include a nonadhesive KT1, standard adhesive KT3+, and advanced adhesive KT5+. KT portfolio slides are validated for use on the company’s PiSmart slide printers and can be used in digital pathology. KT Koverglass, made from Schott D 263M glass, offers high refractive indices and uniform dimensions, resulting in true-to-life color representation and superior clarity, the company says.

BioFire tropical fever panel gets special 510(k) clearance

January 2025—BioMérieux announced that its BioFire Film­Array Tropical Fever panel has received FDA special 510(k) clearance. The panel is capable of testing chikungunya, dengue (serotypes 1, 2, 3, and 4), Leptospira, Plasmodium species, Plasmodium falciparum, and Plasmodium vivax/ovale and has a run time of about 50 minutes on the fully automated BioFire FilmArray 2.0 and Torch systems. Sample prep time is two minutes.

BD, Babson expand access to fingertip blood testing

January 2025—BD and Babson Diagnostics announced an expansion of fingertip blood collection and testing technologies for use by U.S. health systems and other large provider networks in settings like urgent cares, doctors’ offices, and other ambulatory care settings. The blood testing process integrates BD’s MiniDraw capillary blood collection system with Babson’s BetterWay technologies to enable test results from as few as six drops of capillary blood collected from a patient’s finger. Samples can be collected and prepared by any trained health care worker, including those without prior phlebotomy experience.

Thermo Fisher gets clearance for TaqPath COVID-19 PCR kit

January 2025—Thermo Fisher Scientific has received FDA 510(k) clearance for the Applied BioSystems TaqPath COVID-19 diagnostic PCR kit. The kit was first introduced as an EUA test; the 510(k) clearance allows clinical and public health laboratories to convert to an in vitro diagnostic workflow. The kit is intended for use with nasopharyngeal and anterior nasal swab samples and includes assays and controls for the real-time PCR detection of RNA from SARS-CoV-2 emerging virus.

Tempus AI to acquire Ambry Genetics

January 2025—Tempus AI announced it has entered into an agreement to acquire Ambry Genetics. Under the terms of the agreement, Tempus will pay $375 million in cash and $225 million in shares at closing, of which $100 million will be subject to a lock-up agreement until one year post-transaction close. Ambry expects to generate more than $300 million in revenue in 2024 and earnings before interest, taxes, depreciation, and amortization of more than $40 million.

Thermo Fisher, Mainz Biomed to develop a next-gen CRC screening test

January 2025—Mainz Biomed, a Germany-based molecular genetics diagnostic company specializing in cancer diagnostics, announced a collaborative agreement with Thermo Fisher Scientific, through its subsidiary Life Technologies Corp. The companies will jointly develop and potentially commercialize Mainz Biomed’s next-generation colorectal cancer screening product. The test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.

Study finds Aspyre Lung is a rapid, low-input solution for NSCLC testing

January 2025—Biofidelity announced the publication of data that highlight how Aspyre technology addresses the need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer (Herlihy SE, et al. Transl Lung Cancer Res. 2024;13[11]:3083–3095). The study demonstrates that Aspyre Lung reagents can be easily set up and run at external laboratories within a few days, producing reliable results even from challenging sample types.

UllCore BSI test gets breakthrough device designation

January 2025—Deepull announced it has received breakthrough device designation from the FDA for its UllCore bloodstream infection test. The test detects 95 percent of pathogens associated with bloodstream infections that may lead to sepsis, as well as select genetic determinants of antimicrobial resistance, and has a turnaround time of one hour. The real-time multiplex PCR system extracts and analyzes total microbial DNA from 8 mL of whole blood.

RightBio Metrics gastric pH indicators

January 2025—RightBio Metrics has announced the availability of its RightSpot Gastric pH Indicators. The FDA-cleared, CLIA-waived product uses pH to confirm gastric acidity for tubes intended to end in the stomach. Other than an x-ray, the primary identifier of a properly placed nasogastric or orogastric tube tip, RightBio says, is a pH reading of 5.5 or less. Each indicator is individually packaged in high-density copolymer foil with proprietary surface treatment to prevent air, light, and humidity from penetrating and can be stored at temperatures between -40°C and 52°C.

MARKETPLACE

TRENDING